Acadia Pharmaceuticals (ACAD) PT Raised to $37 at Deutsche Bank
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $27.58 -1.57%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 26 | Down: 25 | New: 65
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 26 | Down: 25 | New: 65
Join SI Premium – FREE
Deutsche Bank analyst David Hoang raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $37.00 (from $32.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Google and Blackstone data-center venture hits delays at key sites - Bloomberg
- BMO Capital Starts Carter's (CRI) at Outperform
- BMO Capital Starts Lululemon (LULU) at Underperform
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Deutsche Bank, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
